4.3 Article

3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance

期刊

LEUKEMIA & LYMPHOMA
卷 62, 期 10, 页码 2457-2465

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2021.1919657

关键词

Leukemia; patient-derived 3D culture; drug resistance

资金

  1. Paula C. and Rodger O. Riney Blood Cancer Research Initiative Fund
  2. National Cancer Institute of the National Institutes of Health [NIH] [U54CA199092]
  3. National Center for Advancing Translational Sciences of the NIH [TL1TR002344]
  4. Spencer T. and Ann W. Olin Fellowship for Women in Graduate Study at Washington University

向作者/读者索取更多资源

3D tissue engineered plasma cultures (3DTEPC) derived from CML, AML and CLL patients supported the growth of primary leukemia cells and induced drug resistance, providing a relevant tool for drug screening and personalized medicine.
Chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL) are hematological malignancies that remain incurable despite novel treatments. In order to improve current treatments and clinical efficacy, there remains a need for more complex in vitro models that mimic the intricate human leukemic microenvironment. This study aimed to use 3D tissue engineered plasma cultures (3DTEPC) derived from CML, AML and CLL patients to promote proliferation of leukemic cells for use as a drug screening tool for treatment. 3DTEPC supported the growth of primary CML, AML and CLL cells and also induced significantly more drug resistance in CML, AML and CLL cell lines compared to 2D. The 3DTEPC created a more physiologically relevant environment for leukemia cell proliferation, provided a reliable model for growing leukemia patient samples, and serves as a relevant tool for drug screening and personalized medicine.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据